PPBT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

-0.260

-80.98%

-0.340

+25.55%

Estimates Revision

The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 11.66%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+11.66%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

34.00

Averages

34.00

High

34.00

Current: 0.000

Low

34.00

Averages

34.00

High

34.00

No data

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is -0.39, compared to its 5-year average forward P/E of -6.44. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.44

Current PE

-0.39

Overvalued PE

15.02

Undervalued PE

-27.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.54

Current PS

0.00

Overvalued PS

4.70

Undervalued PS

-1.61

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PPBT News & Events

Events Timeline

No data

News

3.5

2025-12-11Globenewswire

Purple Biotech Reports Significant Anti-Tumor Activity of CAPTN-3 Platform at ESMO IO 2025

3.5

2025-12-11Newsfilter

Purple Biotech Reports New Anti-Tumor Data from CAPTN-3 Platform

2.0

2025-10-30TipRanks

Three Penny Stocks to Keep an Eye on as of October 30, 2025

People Also Watch

Frequently Asked Questions

What is Purple Biotech Ltd (PPBT) stock price today?

The current price of PPBT is 0.6912 USD — it has decreased -2.54 % in the last trading day.

What is Purple Biotech Ltd (PPBT)'s business?

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

What is the price predicton of PPBT Stock?

What is Purple Biotech Ltd (PPBT)'s revenue for the last quarter?

Purple Biotech Ltd revenue for the last quarter amounts to -1.37M USD, decreased -35.91 % YoY.

What is Purple Biotech Ltd (PPBT)'s earnings per share (EPS) for the last quarter?

Purple Biotech Ltd. EPS for the last quarter amounts to -1004000.00 USD, decreased -68.93 % YoY.

What changes have occurred in the market's expectations for Purple Biotech Ltd (PPBT)'s fundamentals?

How many employees does Purple Biotech Ltd (PPBT). have?

Purple Biotech Ltd (PPBT) has 9 emplpoyees as of January 10 2026.

What is Purple Biotech Ltd (PPBT) market cap?

Today PPBT has the market capitalization of 6.24M USD.